Veradermics MANE
NYSE MANE
$152.65 +4.21 (+2.84%)
As of: Nov 11, 2026 · 2:04 PM EST

Veradermics (MANE) Return on Capital Employed [ROCE] (2026)

Updated

Veradermics (MANE) posted Return on Capital Employed [ROCE] of -14.74% for Q2 2026.

Analysis

Veradermics (MANE) Return on Capital Employed [ROCE] (2026) Analysis & Trends

For FY2025, Veradermics' Return on Capital Employed [ROCE] came in at -76.21%.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROCE (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 35.41%
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 17.52%
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 21.60%
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 4.65%
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 9.91%
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 17.37%
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -6.15%
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 11.32%
10 Veradermics 822.06 Mn -1.33 Bn - -13.80%
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 -13.80%
Jun 30, 2026 -17.13%
Mar 31, 2026 -33.28%
API Access

Veradermics Return on Capital Employed [ROCE] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-capital-employed-%5Broce%5D&ticker=MANE&period=max&api_key=YOUR_API_KEY